Peggy Wong

643 total citations
21 papers, 415 citations indexed

About

Peggy Wong is a scholar working on Pharmacology, Cardiology and Cardiovascular Medicine and Organic Chemistry. According to data from OpenAlex, Peggy Wong has authored 21 papers receiving a total of 415 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pharmacology, 8 papers in Cardiology and Cardiovascular Medicine and 6 papers in Organic Chemistry. Recurrent topics in Peggy Wong's work include Inflammatory mediators and NSAID effects (10 papers), Synthesis of β-Lactam Compounds (6 papers) and Antiplatelet Therapy and Cardiovascular Diseases (4 papers). Peggy Wong is often cited by papers focused on Inflammatory mediators and NSAID effects (10 papers), Synthesis of β-Lactam Compounds (6 papers) and Antiplatelet Therapy and Cardiovascular Diseases (4 papers). Peggy Wong collaborates with scholars based in United States, Belgium and United Kingdom. Peggy Wong's co-authors include Keith Gottesdiener, Scott A. Waldman, Howard Greenberg, Barry J. Gertz, Lisa Gillen, Martha Huntington, Arturo G. Porras, Nancy Agrawal, Inge De Lepeleire and B. J. Gertz and has published in prestigious journals such as Gastroenterology, Clinical Pharmacology & Therapeutics and Diabetes Obesity and Metabolism.

In The Last Decade

Peggy Wong

21 papers receiving 395 citations

Peers

Peggy Wong
Gabriele Merciaro Italy
Paul J. DeSchepper United States
Cristina Varas Spain
G Lévy United States
Lisa M. Antes United States
Tai‐Juan Aw Australia
Victor Skrinska United States
H Weisenberger Germany
Dany Salvail Canada
Mary Dixon United States
Gabriele Merciaro Italy
Peggy Wong
Citations per year, relative to Peggy Wong Peggy Wong (= 1×) peers Gabriele Merciaro

Countries citing papers authored by Peggy Wong

Since Specialization
Citations

This map shows the geographic impact of Peggy Wong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peggy Wong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peggy Wong more than expected).

Fields of papers citing papers by Peggy Wong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peggy Wong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peggy Wong. The network helps show where Peggy Wong may publish in the future.

Co-authorship network of co-authors of Peggy Wong

This figure shows the co-authorship network connecting the top 25 collaborators of Peggy Wong. A scholar is included among the top collaborators of Peggy Wong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peggy Wong. Peggy Wong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhu, Peijuan, Chyi‐Hung Hsu, Chuanpu Hu, et al.. (2020). Application of Trial Simulation in the Design of a Prospective Study for Concentration-QTc Analysis in Support of a Thorough QT Study Waiver. The AAPS Journal. 22(5). 101–101. 1 indexed citations
2.
Li, Wenyu, Thomas Kirchner, Katharine D’Aquino, et al.. (2020). Amino acids are sensitive glucagon receptor‐specific biomarkers for glucagon‐like peptide‐1 receptor/glucagon receptor dual agonists. Diabetes Obesity and Metabolism. 22(12). 2437–2450. 14 indexed citations
3.
Moore, Kenneth Todd, Peggy Wong, Liping Zhang, Guohua Pan, & JoAnne M. Foody. (2018). Influence of age on the pharmacokinetics, pharmacodynamics, efficacy, and safety of rivaroxaban. Current Medical Research and Opinion. 34(12). 2053–2061. 10 indexed citations
4.
Knox, Clayton D., Pieter‐Jan de Kam, Karim Azer, et al.. (2016). Discovery and Clinical Evaluation of MK‐8150, A Novel Nitric Oxide Donor With a Unique Mechanism of Nitric Oxide Release. Journal of the American Heart Association. 5(9). 11 indexed citations
5.
Wong, Peggy, et al.. (2014). Empirical Analysis of Body Constitution and Food Intake in Persons with Type 2 Diabetes from a TCM Perspective. Revista catalana de dret públic (Escola d'Administració Pública de Catalunya (EAPC)). 3(2). 67–80. 2 indexed citations
6.
Chen, Fabian, Edward A. O’Neill, Brian K. Hubbard, et al.. (2011). The effects of simvastatin treatment on plasma lipid-related biomarkers in men with dyslipidaemia. Biomarkers. 16(4). 321–333. 16 indexed citations
7.
Schwartz, Jules I., Thomas L. Hunt, William Smith, et al.. (2009). The Effect of Etoricoxib on the Pharmacokinetics of Oral Contraceptives in Healthy Participants. The Journal of Clinical Pharmacology. 49(7). 807–815. 9 indexed citations
8.
Krishna, Rajesh, Peggy Wong, Inge De Lepeleire, et al.. (2008). Lack of Erectogenic Activity of a Novel Selective Melanocortin‐4 Receptor Agonist in a Clinical Experimental Model. The Journal of Clinical Pharmacology. 48(10). 1237–1241. 7 indexed citations
9.
Gottesdiener, Keith, Nancy Agrawal, Arturo G. Porras, et al.. (2003). Effects of Renal Insufficiency and Hemodialysis on the Pharmacokinetics of Rofecoxib. American Journal of Therapeutics. 10(4). 252–258. 5 indexed citations
10.
Dallob, Aimée, Christopher J. Hawkey, Howard Greenberg, et al.. (2003). Characterization of Etoricoxib, a Novel, Selective COX-2 Inhibitor. The Journal of Clinical Pharmacology. 43(6). 573–585. 8 indexed citations
11.
Dallob, Aimée, Christopher J. Hawkey, Howard Greenberg, et al.. (2003). Characterization of Etoricoxib, a Novel, Selective COX‐2 Inhibitor. The Journal of Clinical Pharmacology. 43(6). 573–585. 76 indexed citations
12.
Hecken, Anne Van, Inge De Lepeleire, Peggy Wong, et al.. (2003). Platelet aggregation inhibition by naproxen, rofecoxib, diclofenac, ibuprofen, and meloxicam. Clinical Pharmacology & Therapeutics. 73(2). 1 indexed citations
13.
Wagner, John A., Walter K. Kraft, Joanne Burke, et al.. (2001). THE COX-2 INHIBITOR ETORICOXIB DID NOT ALTER THE ANTI-PLATELET EFFECTS OF LOW-DOSE ASPIRIN IN HEALTHY VOLUNTEERS.. Arthritis & Rheumatism. 44(9). 5 indexed citations
14.
Gottesdiener, Keith, Clare T. Atherton, Barry J. Gertz, et al.. (2001). Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production. Gastroenterology. 120(4). 867–873. 49 indexed citations
15.
Depré, Marleen, Elliot Ehrich, Anne Van Hecken, et al.. (2000). Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. European Journal of Clinical Pharmacology. 56(2). 167–174. 78 indexed citations
16.
Greenberg, Howard, Keith Gottesdiener, Martha Huntington, et al.. (2000). A New Cyclooxygenase‐2 Inhibitor, Rofecoxib (VIOXX®), Did Not Alter the Antiplatelet Effects of Low‐Dose Aspirin in Healthy Volunteers. The Journal of Clinical Pharmacology. 40(12). 1509–1515. 35 indexed citations
17.
Calder, Nicole, Aimée Dallob, Peggy Wong, et al.. (2000). Evidence that the COX-2 specific inhibitor rofecoxib at 50 mg spares gastric mucosal prostaglandin synthesis in human. Gastroenterology. 118(4). A253–A253. 7 indexed citations
18.
Greenberg, Howard, Keith Gottesdiener, Martha Huntington, et al.. (2000). A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.. PubMed. 40(12 Pt 2). 1509–15. 63 indexed citations
19.
20.
Ehrich, Elliot, D Hilliard, Arturo G. Porras, et al.. (1999). Demonstration of specific COX-2 inhibition by MK-966 in humans with supratherapeutic doses. Clinical Pharmacology & Therapeutics. 65(2). 164–164. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gabriele Merciaro Breakdown of academic impact, for papers by Paul J. DeSchepper Breakdown of academic impact, for papers by Cristina Varas Breakdown of academic impact, for papers by G Lévy Breakdown of academic impact, for papers by Lisa M. Antes Breakdown of academic impact, for papers by Tai‐Juan Aw Breakdown of academic impact, for papers by Victor Skrinska Breakdown of academic impact, for papers by H Weisenberger Breakdown of academic impact, for papers by Dany Salvail Breakdown of academic impact, for papers by Mary Dixon
Rankless by CCL
2026